Wow. When I started blogging about GIK valuations, I knew there was a major issue, but didn’t quite grasp how big it really is.
The beginning point of my discussion was a Forbes article, by William P. Barrett: Donated Pills Make Some Charities Look Too Good on Paper. In this post I will look at the impact of a change in accounting rules on the valuation of GIKs.
Additional background
Several articles by Caroline Preston in The Chronicle of Philanthropy outline the issues. One deworming medicine, Mebendazole, seems to be the biggest issue. In her article Aid Charities’ Accounting Practices Draw Criticism, she quantifies the significance of that one med: (more…)